Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery: A Prospective...

Area of Science:

• Ophthalmology
• Corneal Science
• Refractive Surgery

Background:

• Dry eye disease (DED) is a common comorbidity in patients undergoing cataract surgery.
• Perfluorohexyloctane ophthalmic solution (PFHO) is approved for DED treatment, forming a protective tear film layer.
• PFHO's long ocular residence time prompted an investigation into its potential impact on preoperative measurements for cataract surgery.

Purpose of the Study:

• To evaluate the effect of perioperative perfluorohexyloctane ophthalmic solution (PFHO) on biometry and keratometry measurements.
• To assess whether PFHO use influences postoperative refractive accuracy in patients undergoing cataract surgery.
• To determine the impact of PFHO on dry eye disease (DED) signs and symptoms in this patient population.

Main Methods:

• Phase 4, multicenter, open-label, single-arm study.
• Enrolled patients with DED undergoing phacoemulsification with intraocular lens (IOL) implantation.
• Patients used PFHO bilaterally for 30 days preoperatively and 30 days postoperatively; primary endpoint was refractive prediction error.

Main Results:

• The mean absolute deviation between manifest refraction and predicted refractive error was -0.027 ± 0.167 D (p=0.1385).
• 94.2% of eyes had predicted refractive error within ±0.3 D post-PFHO treatment.
• PFHO significantly improved DED signs and symptoms (p < 0.0001) and increased the percentage of eyes with calculated IOL power within ±0.50 D of correct power (83.7% vs. 72.1%).

Conclusions:

• Perioperative PFHO use does not negatively affect preoperative biometry, keratometry, or refractive prediction accuracy in cataract surgery patients.
• PFHO treatment led to significant improvements in dry eye disease (DED) signs and symptoms.
• High percentages of patients achieved excellent visual acuity (≥20/20) post-surgery.